22 research outputs found
ΠΠ°Π»Π΅ΠΊΡΠΈΠ½-3 Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠΎΠ»ΠΈΠ΄Π½ΡΡ ΠΎΡΠ³Π°Π½ΠΎΠ²: ΡΠΎΠ»Ρ Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° ΠΈ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ
Galectin-3 (Gal-3) is an important regulator of cell adhesion, migration, proliferation, differentiation and apoptosis under pathophysiological conditions. It plays a crucial role in diseases associated with chronic inflammation and fibrosis. In recent years, there have been reports indicating changes in serum Gal-3 levels in solid organ transplant recipients in the verification of kidney, liver, heart and lung transplant pathologies. Studies on Gal-3 levels and dynamics in solid organ recipients may serve to assess graft conditions using new minimally invasive methods and to identify therapeutic targets for personalized therapy. The first clinical trial data on Gal-3 pharmacological inhibition are emerging. This review summarizes the current understanding of the role of Gal-3 in transplant pathology and the prospects for its use as a diagnostic marker and therapeutic target in solid organ recipients.ΠΠ°Π»Π΅ΠΊΡΠΈΠ½-3 β Π²Π°ΠΆΠ½ΡΠΉ ΡΠ΅Π³ΡΠ»ΡΡΠΎΡ ΠΏΡΠΎΡΠ΅ΡΡΠΎΠ² ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ Π°Π΄Π³Π΅Π·ΠΈΠΈ, ΠΌΠΈΠ³ΡΠ°ΡΠΈΠΈ, ΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΠΈ, Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²ΠΊΠΈ ΠΈ Π°ΠΏΠΎΠΏΡΠΎΠ·Π° ΠΏΡΠΈ ΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΎΡΡΠΎΡΠ½ΠΈΡΡ
. ΠΡΠΎΠ±ΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π³Π°Π»Π΅ΠΊΡΠΈΠ½-3 ΠΈΠΌΠ΅Π΅Ρ ΠΏΡΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, ΡΠ²ΡΠ·Π°Π½Π½ΡΡ
Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΠ΅ΠΌ ΠΈ ΡΠΈΠ±ΡΠΎΠ·ΠΎΠΌ. ΠΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ Π³ΠΎΠ΄Ρ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Π³Π°Π»Π΅ΠΊΡΠΈΠ½Π°-3 Π² ΠΊΡΠΎΠ²ΠΈ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠΎΠ»ΠΈΠ΄Π½ΡΡ
ΠΎΡΠ³Π°Π½ΠΎΠ² ΠΏΡΠΈ Π²Π΅ΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° ΠΏΠΎΡΠΊΠΈ, ΠΏΠ΅ΡΠ΅Π½ΠΈ, ΡΠ΅ΡΠ΄ΡΠ° ΠΈ Π»Π΅Π³ΠΊΠΈΡ
. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ ΠΈ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ Π³Π°Π»Π΅ΠΊΡΠΈΠ½Π°-3 Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠΎΠ»ΠΈΠ΄Π½ΡΡ
ΠΎΡΠ³Π°Π½ΠΎΠ² ΠΌΠΎΠ³ΡΡ ΡΠ»ΡΠΆΠΈΡΡ Π΄Π»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° Ρ ΠΏΠΎΠΌΠΎΡΡΡ Π½ΠΎΠ²ΡΡ
ΠΌΠ°Π»ΠΎΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΠΈ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠΈΡΠ΅Π½Π΅ΠΉ Π΄Π»Ρ ΠΏΠ΅ΡΡΠΎΠ½ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΠΎΡΠ²Π»ΡΡΡΡΡ ΠΏΠ΅ΡΠ²ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΎ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ Π³Π°Π»Π΅ΠΊΡΠΈΠ½Π°-3. Π Π½Π°ΡΡΠΎΡΡΠ΅ΠΌ ΠΎΠ±Π·ΠΎΡΠ΅ ΡΡΠΌΠΌΠΈΡΠΎΠ²Π°Π½Ρ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΎ ΡΠΎΠ»ΠΈ Π³Π°Π»Π΅ΠΊΡΠΈΠ½Π°-3 Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° ΠΈ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π°Ρ
Π΅Π³ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΌΠ°ΡΠΊΠ΅ΡΠ° ΠΈ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΌΠΈΡΠ΅Π½ΠΈ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠΎΠ»ΠΈΠ΄Π½ΡΡ
ΠΎΡΠ³Π°Π½ΠΎΠ²
Π‘Π²ΡΠ·Ρ ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΏΠΎΡΡΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ
Objective: to analyze the correlation between the expression levels of microRNA-101, microRNA-142, microRNA-27, microRNA-339, and microRNA-424 and the plasma concentrations of biomarkers that are potentially significant for the diagnosis of post-transplant complications in heart recipients. Materials and methods. The study enrolled 72 heart recipients, among whom were 56 men (77.8%). The average age of recipients was 48.6 Β± 10.9 (16 to 70) years. There were 38 patients with severe chronic heart failure, among whom were 29 men (76.3%). Patientsβ mean age was 48.8 Β± 9.9 (26 to 70) years. The control group consisted of 12 healthy individuals who did not differ significantly by sex and age. microRNA expression levels in blood plasma were measured via quantitative polymerase chain reaction. Plasma concentrations of VEGF-A, PLGF, MCP-1, and sCD40L were determined using a multiplex method. ST2 and Galectin-3 concentrations were measured via enzyme-linked immunosorbent assay. Results. Patients with end-stage chronic heart failure were found to have significantly higher expression levels of microRNA-27, microRNA-339 and microRNA-424 in blood plasma compared with the healthy individuals. In potential heart recipients, the expression le vels of microRNA-339 and microRNA-424 correlated with serum galectin-3 concentrations, microRNA-101 expression levels correlated with PLGF-1 concentrations, while microRNA-27 expression levels correlated with plasma MCP-1 concentrations. In the early post-transplant period, the expression levels of microRNA-101, microRNA-339, and microRNA-424 in heart recipients were significantly lower than in patients with severe chronic heart failure. In the early post-transplant period (one year or more after transplantation), microRNA-101 and microRNA-27 expression levels were significantly higher than in heart recipients. A year or more after transplantation, the following correlations were found in heart recipients: microRNA-142 expression level correlated with serum levels of galectin-3 (p = 0.05), microRNA-27 and microRNA-424 expression levels correlated with ST2 concentrations (p = 0.02), microRNA-27 expression level correlated with PLGF-1 concentrations (p = 0.02), while microRNA-101 expression level correlated with serum levels of PAPP-A (p = 0.05). Conclusion. In heart recipients, the expression levels of microRNA-142, microRNA-27, microRNA-424, and microRNA-101 correlate with the concentration levels of biomarkers of fibrosis (Galectin-3), rejection (ST2), neoangiogenesis (PLGF), and tissue destruction (PAPP-A). A comprehensive analysis of pre- and post-translational markers may open up new perspectives in diagnosis, assessment of the risks of post-transplant complications, and in understanding the processes leading to their development.Π¦Π΅Π»Ρ: Π°Π½Π°Π»ΠΈΠ· ΡΠ²ΡΠ·ΠΈ ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-101, ΠΌΠΈΠΊΡΠΎΠ ΠΠ-142, ΠΌΠΈΠΊΡΠΎΠ ΠΠ-27, ΠΌΠΈΠΊΡΠΎΠ ΠΠ-339 ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-424 Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ², ΡΡΠ°ΡΡΠ²ΡΡΡΠΈΡ
Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ ΠΈ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎ Π·Π½Π°ΡΠΈΠΌΡΡ
Π΄Π»Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΏΠΎΡΡΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ°. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 72 ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠ° ΡΠ΅ΡΠ΄ΡΠ°, ΡΡΠ΅Π΄ΠΈ Π½ΠΈΡ
ΠΌΡΠΆΡΠΈΠ½ β 56 (77,8%), ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠΎΡΡΠ°Π²ΠΈΠ» 48,6 Β± 10,9 (ΠΎΡ 16 Π΄ΠΎ 70) Π³ΠΎΠ΄Π°, ΠΈ 38 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΡΠΆΠ΅Π»ΠΎΠΉ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡΡ, ΡΡΠ΅Π΄ΠΈ Π½ΠΈΡ
ΠΌΡΠΆΡΠΈΠ½ β 29 (76,3%), ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΡΠΎΡΡΠ°Π²ΠΈΠ» 48,8 Β± 9,9 (ΠΎΡ 26 Π΄ΠΎ 70) Π³ΠΎΠ΄Π°. ΠΡΡΠΏΠΏΡ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 12 Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π»ΠΈΡ, Π·Π½Π°ΡΠΈΠΌΠΎ Π½Π΅ ΠΎΡΠ»ΠΈΡΠ°ΡΡΠΈΡ
ΡΡ ΠΏΠΎ ΠΏΠΎΠ»Ρ ΠΈ Π²ΠΎΠ·ΡΠ°ΡΡΡ. Π£ΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΡΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ VEGF-A, PLGF, MCP-1 ΠΈ sCD40L Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΌΡΠ»ΡΡΠΈΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄Π°. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ST2 ΠΈ Π³Π°Π»Π΅ΠΊΡΠΈΠ½Π°-3 Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Ρ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-27, ΠΌΠΈΠΊΡΠΎΠ ΠΠ-339 ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-424 Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ΅ΡΠΌΠΈΠ½Π°Π»ΡΠ½ΠΎΠΉ ΡΡΠ°Π΄ΠΈΠ΅ΠΉ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΠΎ Π·Π΄ΠΎΡΠΎΠ²ΡΠΌΠΈ Π»ΠΈΡΠ°ΠΌΠΈ. Π£ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-339, ΠΌΠΈΠΊΡΠΎΠ ΠΠ-424 ΠΊΠΎΡΡΠ΅Π»ΠΈΡΠΎΠ²Π°Π» Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ Π³Π°Π»Π΅ΠΊΡΠΈΠ½Π°-3, ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-101 β Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ PLGF-1, ΡΡΠΎΠ²Π΅Π½Ρ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-27 β Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ MCP-1. Π ΡΠ°Π½Π½ΠΈΠ΅ ΡΡΠΎΠΊΠΈ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-101, ΠΌΠΈΠΊΡΠΎΠ ΠΠ-339 ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-424 Π±ΡΠ» Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π½ΠΈΠΆΠ΅, ΡΠ΅ΠΌ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΡΠΆΠ΅Π»ΠΎΠΉ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡΡ. Π§Π΅ΡΠ΅Π· Π³ΠΎΠ΄ ΠΈ Π±ΠΎΠ»Π΅Π΅ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-101 ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-27 Π±ΡΠ» Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π²ΡΡΠ΅, ΡΠ΅ΠΌ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° Π² ΡΠ°Π½Π½ΠΈΠ΅ ΡΡΠΎΠΊΠΈ. Π£ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° ΡΠΏΡΡΡΡ Π³ΠΎΠ΄ ΠΈ Π±ΠΎΠ»Π΅Π΅ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π° ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΎΠ½Π½Π°Ρ ΡΠ²ΡΠ·Ρ ΠΌΠ΅ΠΆΠ΄Ρ ΡΡΠΎΠ²Π½Π΅ΠΌ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-142 ΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ Π³Π°Π»Π΅ΠΊΡΠΈΠ½Π°-3 (p = 0,05), ΡΡΠΎΠ²Π½Π΅ΠΌ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-27, ΠΌΠΈΠΊΡΠΎΠ ΠΠ-424 ΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ ST2 (p = 0,02), ΡΡΠΎΠ²Π½Π΅ΠΌ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-27 ΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ PLGF-1 (p = 0,02), ΡΡΠΎΠ²Π½Π΅ΠΌ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-101 ΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ PAPP-A (p = 0,05). ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π£ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° Π²Π΅Π»ΠΈΡΠΈΠ½Π° ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-142, ΠΌΠΈΠΊΡΠΎΠ ΠΠ-27, ΠΌΠΈΠΊΡΠΎΠ ΠΠ-424 ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-101 ΡΠ²ΡΠ·Π°Π½Π° Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΡΠΈΠ±ΡΠΎΠ·Π° (Π³Π°Π»Π΅ΠΊΡΠΈΠ½-3), ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ (ST2), Π½Π΅ΠΎΠ°Π½Π³ΠΈΠΎΠ³Π΅Π½Π΅Π·Π° (PLGF) ΠΈ Π΄Π΅ΡΡΡΡΠΊΡΠΈΠΈ ΡΠΊΠ°Π½Π΅ΠΉ (PAPP-A). ΠΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· Π΄ΠΎ- ΠΈ ΠΏΠΎΡΡΡΡΠ°Π½ΡΠ»ΡΡΠΈΠΎΠ½Π½ΡΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΌΠΎΠΆΠ΅Ρ ΠΎΡΠΊΡΡΡΡ Π½ΠΎΠ²ΡΠ΅ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Ρ ΠΊΠ°ΠΊ Π² Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅, ΠΎΡΠ΅Π½ΠΊΠ΅ ΡΠΈΡΠΊΠΎΠ² ΠΏΠΎΡΡΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ, ΡΠ°ΠΊ ΠΈ Π² ΠΏΠΎΠ½ΠΈΠΌΠ°Π½ΠΈΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠΎΠ², Π²Π΅Π΄ΡΡΠΈΡ
ΠΊ ΠΈΡ
ΡΠ°Π·Π²ΠΈΡΠΈΡ
ST2 ΠΠ Π ΠΠ’Π’ΠΠ ΠΠΠΠΠ Π’Π ΠΠΠ‘ΠΠΠΠΠ’ΠΠ ΠΠΠΠΠΠΠΠ Π‘ΠΠ ΠΠ¦Π
This review summarizes the current literature devoted to the analysis of prognostic role of ST2 biomarker in rejection of the transplanted heart. ST2 is one of the most promising diagnostic markers of the development and severity of heart failure as well as the mortality risk in patients with cardiovascular diseases. ST2 is expressed in cardiomyocytes in response to a variety of pathological processes and mechanical damage to the heart, which allows diagnosing cardiovascular diseases before clinical manifestations. Presumably, measuring the level of ST2 in heart transplant may have diagnostic and prognostic value in the assessment of graft and risk of rejection. Currently, accumulated clinical data on the role of given biomarker in heart transplantation are not enough, and further research on the relation of ST2 levels with different clinical and laboratory parameters in heart recipients is necessary.Β ΠΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΠΏΠΎΡΠ²ΡΡΠ΅Π½ Π°Π½Π°Π»ΠΈΠ·Ρ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΈΜ ΡΠΎΠ»ΠΈ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠ° ST2 ΠΏΡΠΈ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΠΈ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΄ΡΠ°. ST2 ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ· Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΈ ΡΡΠΆΠ΅ΡΡΠΈ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΈΜ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠΈΡΠΊΠ° ΡΠΌΠ΅ΡΡΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΡΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ. ST2 ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡΡΠ΅ΡΡΡ Π² ΠΊΠ°ΡΠ΄ΠΈΠΎΠΌΠΈΠΎΡΠΈΡΠ°Ρ
Π² ΠΎΡΠ²Π΅Ρ Π½Π° ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΎΡΠ΅ΡΡΡ ΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠ΅ ΠΌΠ΅Ρ
Π°Π½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ Π² ΡΠ΅ΡΠ΄ΡΠ΅, ΡΡΠΎ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠΎΠ²Π°ΡΡ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΡΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π΅ΡΠ΅ Π΄ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΈΜ. ΠΡΠ΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ ST2 ΠΏΡΠΈ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΡΠ΅ΡΠ΄ΡΠ° ΠΌΠΎΠΆΠ΅Ρ ΠΈΠΌΠ΅ΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠΈ ΠΎΡΠ΅Π½ΠΊΠ΅ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° ΠΈ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ. Π Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
Π΄Π°Π½Π½ΡΡ
ΠΎ ΡΠΎΠ»ΠΈ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠ° ΠΏΡΠΈ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΡΠ΅ΡΠ΄ΡΠ° Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½ΠΎ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ, ΠΈ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΡ Π΄Π°Π»ΡΠ½Π΅ΠΈΜΡΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ²ΡΠ·ΠΈ ΡΡΠΎΠ²Π½Ρ ST2 Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΠΌΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ°.
ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-101 ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-27 ΠΏΡΠΈ ΠΎΡΡΡΠΎΠΌ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΠΈ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΄ΡΠ°
Objective: to determine the diagnostic value of miRNA-101 and miRNA-27 expression levels for acute hearttransplant rejection. Materials and methods. The study enrolled 46 heart recipients, among whom were 36 menΒ (78.3%); the average age of recipients was 47.7 = 10.8 (16 to 67) years. Serum microRNA expression levels wereΒ measured via quantitative polymerase chain reaction (PCR). Graft rejection was verified through morphologicalΒ analysis of endomyocardial biopsy specimens. Results. The expression levels of miRNA-101 and miRNA-27Β in recipients with acute graft rejection are significantly lower than in recipients without rejection (p = 0.04 andΒ p = 0.03, respectively). When the miRNA-101 expression level is below the determined threshold value, the riskΒ Β of developing acute graft rejection increases 1.8 times (RR = 1.8 [95% CI 1.13β3.01]). When the miRNA-27Β expression level is below the determined threshold value, the risk of developing acute graft rejection increasesΒ 1.9 times (RR = 1.9 [95% CI 1.12β3.37]). Simultaneous decrease in the expression levels of miRNA-101 andΒ miRNA-27 below the determined threshold values increases the likelihood of acute graft rejection by 2.0 timesΒ (RR = 2.0 [95% CI 1.16β3.36]). Conclusion. The serum miRNA-101 and miRNA-27 expression levels are ofΒ diagnostic value for acute graft rejection in heart recipients.Π¦Π΅Π»Ρ: ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-101 ΠΈΒ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-27 Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΠΎΡΡΡΠΎΠ³ΠΎ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ°. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅Β Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 46 ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ°, ΡΡΠ΅Π΄ΠΈ Π½ΠΈΡ
ΠΌΡΠΆΡΠΈΠ½ β 36 (78,3%); ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠΎΡΡΠ°Π²ΠΈΠ»Β 47,7 Β± 10,8 (ΠΎΡ 16 Π΄ΠΎ 67) Π³ΠΎΠ΄Π°. Π£ΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΡΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌΒ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ (ΠΠ¦Π ). ΠΠ΅ΡΠΈΡΠΈΠΊΠ°ΡΠΈΡ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡΒ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈΒ Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² ΡΠ½Π΄ΠΎΠΌΠΈΠΎΠΊΠ°ΡΠ΄ΠΈΠ°Π»ΡΠ½ΡΡ
Π±ΠΈΠΎΠΏΡΠ°ΡΠΎΠ². Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ.Β Π£ΡΠΎΠ²Π½ΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-101 ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-27 Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΎΡΡΡΡΠΌ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ°Β Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π½ΠΈΠΆΠ΅ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠ°ΠΌΠΈ Π±Π΅Π· ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ (Ρ = 0,04 ΠΈ Ρ = 0,03 ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ).Β ΠΡΠΈ ΡΡΠΎΠ²Π½Π΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-101 Π½ΠΈΠΆΠ΅ Π½Π°ΠΉΠ΄Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΠΎΡΠΎΠ³ΠΎΠ²ΠΎΠ³ΠΎ Π·Π½Π°ΡΠ΅Π½ΠΈΡ Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΡ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΎΡΡΡΠΎΠ³ΠΎ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡΒ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° Π²ΠΎΠ·ΡΠ°ΡΡΠ°Π΅Ρ Π² 1,8 ΡΠ°Π·Π° (RR = 1,8 [95% ΠΠ 1,13β3,01]). ΠΡΠΈ ΡΡΠΎΠ²Π½Π΅Β ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-27 Π½ΠΈΠΆΠ΅ Π½Π°ΠΉΠ΄Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΠΎΡΠΎΠ³ΠΎΠ²ΠΎΠ³ΠΎ Π·Π½Π°ΡΠ΅Π½ΠΈΡ Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΡ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΎΡΡΡΠΎΠ³ΠΎΒ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° Π²ΠΎΠ·ΡΠ°ΡΡΠ°Π΅Ρ Π² 1,9 ΡΠ°Π·Π° (RR = 1,9 [95% ΠΠ 1,12β3,37]). ΠΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅Β ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-101 ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-27 Π½ΠΈΠΆΠ΅ Π½Π°ΠΉΠ΄Π΅Π½Π½ΡΡ
ΠΏΠΎΡΠΎΠ³ΠΎΠ²ΡΡ
Π·Π½Π°ΡΠ΅Π½ΠΈΠΉ ΠΏΠΎΠ²ΡΡΠ°Π΅ΡΒ Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΡ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΎΡΡΡΠΎΠ³ΠΎ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° Π² 2,0 ΡΠ°Π·Π° (RR = 2,0 [95% ΠΠ 1,16β3,36]).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π£ΡΠΎΠ²Π½ΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-101 ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ-27 ΠΎΠ±Π»Π°Π΄Π°ΡΡΒ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡΡΒ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΠΎΡΡΡΠΎΠ³ΠΎ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ°.
Π£ΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ Π² ΡΠ°Π½Π½ΠΈΠ΅ ΠΈ ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΡΠ΅ ΡΡΠΎΠΊΠΈ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ°
Objective: to conduct comparative analysis of the expression levels of microRNA-101, microRNA-142, microRNA- 27, microRNA-339 and microRNA-424 in patients with severe chronic heart failure and in heart recipients in the early and long-term period following heart transplantation and to determine the association with acute transplant rejection. Materials and methods. The study included 46 heart recipients, among whom were 36 men (78.3%); the average age of the recipients was 47.7 Β± 10.8 (16 to 67) years, and 12 patients with end-stage chronic heart failure, among whom were 8 men (66.7%); the average age of the patients was 46.1 Β± 6.4 (37 to 64) years. The control group consisted of 12 healthy individuals, not significantly different by gender and age. microRNA expression levels in blood plasma were determined through quantitative polymerase chain reaction (Q-PCR). Transplant rejection was verified via morphological analysis of endomyocardial biopsy specimens. Results. Blood plasma of patients with end-stage chronic heart failure had significantly higher expression rates of microRNA-101, microRNA-27, microRNA-339 and microRNA-424 than in healthy individuals (p < 0.02). In the early stages following transplantation, the expression levels of microRNA-101 and microRNA-27 in heart recipients were significantly lower than in patients with severe chronic heart failure (p < 0.003). A year or more after transplantation, there were no significant differences in the expression levels of microRNA-101, microRNA- 142, and microRNA-339 in heart recipients and in healthy individuals. In recipients with acute rejection, the expression levels of microRNA-101 and microRNA-27 significantly differed from that of recipients without signs of rejection (p = 0.04 and p = 0.03, respectively). Conclusion. The obtained data on changes in the expression levels of microRNA-101 and microRNA-27 in heart recipients with acute transplant rejection suggests possible diagnostic value of these biomarkers in determining the risk of rejection.Π¦Π΅Π»Ρ: ΠΏΡΠΎΠ²Π΅ΡΡΠΈ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ- 101, ΠΌΠΈΠΊΡΠΎΠ ΠΠ- 142, ΠΌΠΈΠΊΡΠΎΠ ΠΠ- 27, ΠΌΠΈΠΊΡΠΎΠ ΠΠ- 339 ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ- 424 Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΡΠΆΠ΅Π»ΠΎΠΉ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡΡ ΠΈ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° Π² ΡΠ°Π½Π½ΠΈΠ΅ ΠΈ ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΡΠ΅ ΡΡΠΎΠΊΠΈ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ ΡΠ²ΡΠ·Ρ Ρ ΠΎΡΡΡΡΠΌ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ°. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 46 ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ°, ΡΡΠ΅Π΄ΠΈ Π½ΠΈΡ
36 (78,3%) ΠΌΡΠΆΡΠΈΠ½ (ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠΎΡΡΠ°Π²ΠΈΠ» 47,7 Β± 10,8 (ΠΎΡ 16 Π΄ΠΎ 67) Π³ΠΎΠ΄Π°) ΠΈ 12 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ΅ΡΠΌΠΈΠ½Π°Π»ΡΠ½ΠΎΠΉ ΡΡΠ°Π΄ΠΈΠ΅ΠΉ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ, ΡΡΠ΅Π΄ΠΈ Π½ΠΈΡ
8 (66,7%) ΠΌΡΠΆΡΠΈΠ½ (ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΡΠΎΡΡΠ°Π²ΠΈΠ» 46,1 Β± 6,4 (ΠΎΡ 37 Π΄ΠΎ 64) Π³ΠΎΠ΄Π°). ΠΡΡΠΏΠΏΡ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 12 Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π»ΠΈΡ, Π·Π½Π°ΡΠΈΠΌΠΎ Π½Π΅ ΠΎΡΠ»ΠΈΡΠ°ΡΡΠΈΡ
ΡΡ ΠΏΠΎ ΠΏΠΎΠ»Ρ ΠΈ Π²ΠΎΠ·ΡΠ°ΡΡΡ. Π£ΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΡΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ (ΠΠ¦Π ). ΠΠ΅ΡΠΈΡΠΈΠΊΠ°ΡΠΈΡ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² ΡΠ½Π΄ΠΎΠΌΠΈΠΎΠΊΠ°ΡΠ΄ΠΈΠ°Π»ΡΠ½ΡΡ
Π±ΠΈΠΎΠΏΡΠ°ΡΠΎΠ². Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Ρ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ- 101, ΠΌΠΈΠΊΡΠΎΠ ΠΠ- 27, ΠΌΠΈΠΊΡΠΎΠ ΠΠ- 339 ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ- 424 Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ΅ΡΠΌΠΈΠ½Π°Π»ΡΠ½ΠΎΠΉ ΡΡΠ°Π΄ΠΈΠ΅ΠΉ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΠΎ Π·Π΄ΠΎΡΠΎΠ²ΡΠΌΠΈ Π»ΠΈΡΠ°ΠΌΠΈ (p < 0,02). Π ΡΠ°Π½Π½ΠΈΠ΅ ΡΡΠΎΠΊΠΈ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ- 101 ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ- 27 Π±ΡΠ» Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π½ΠΈΠΆΠ΅, ΡΠ΅ΠΌ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΡΠΆΠ΅Π»ΠΎΠΉ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡΡ (p < 0,003). Π§Π΅ΡΠ΅Π· Π³ΠΎΠ΄ ΠΈ Π±ΠΎΠ»Π΅Π΅ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΠ΅ ΡΠ°Π·Π»ΠΈΡΠΈΡ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ- 101, ΠΌΠΈΠΊΡΠΎΠ ΠΠ- 142 ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ- 339 Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° ΠΈ Ρ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π»ΠΈΡ ΠΎΡΡΡΡΡΡΠ²ΠΎΠ²Π°Π»ΠΈ. Π£ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΎΡΡΡΡΠΌ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ- 101 ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ- 27 Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΠΎΡΠ»ΠΈΡΠ°Π»ΡΡ ΠΎΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π±Π΅Π· ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ² ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ (Ρ = 0,04 ΠΈ Ρ = 0,03 ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ). ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΎΠ± ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΈ ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ- 101 ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ- 27 Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° Ρ ΠΎΡΡΡΡΠΌ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠΈΡΡ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΠ΅ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΡΡΠΈΡ
Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π΄Π»Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ
ΠΠΈΠΊΡΠΎ-Π ΠΠ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π»Π΅Π³ΠΊΠΈΡ : ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ
This review summarizes the current literature devoted to the analysis of diagnostic role of biomarkers in rejection of the transplanted lung. Numerous researches have focused on small non-coding RNAs (micro-RNA) that regulate gene expression and affect various cell functions. Variations in the concentration of different micro-RNA have been shown in some pathological processes, including rejection of solid organs. Probably, measuring the level of micro-RNA in lung transplant may have value in the assessment of risk of rejection and possibility of minimizing immunosuppressive therapy. The accumulation of clinical data on the correlation of profiles of various biomarkers with clinical and laboratory parameters in lung recipients will help in finding non-invasive methods for the diagnosis rejection and improving long-term results of transplantation.ΠΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΠΏΠΎΡΠ²ΡΡΠ΅Π½ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΠΌ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ², ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎ ΠΏΡΠΈΠ³ΠΎΠ΄Π½ΡΡ
Π΄Π»Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π»Π΅Π³ΠΊΠΈΡ
. Π Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ Π±ΠΎΠ»ΡΡΠΎΠΉ ΠΈΠ½ΡΠ΅ΡΠ΅Ρ Π²ΡΠ·ΡΠ²Π°Π΅Ρ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΠΌΠ°Π»ΡΡ
Π½Π΅ΠΊΠΎΠ΄ΠΈΡΡΡΡΠΈΡ
Π ΠΠ (ΠΌΠΈΠΊΡΠΎ-Π ΠΠ), ΡΠ΅Π³ΡΠ»ΠΈΡΡΡΡΠΈΡ
ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π³Π΅Π½ΠΎΠ² ΠΈ Π²Π»ΠΈΡΡΡΠΈΡ
Π½Π° ΡΠ°Π·Π»ΠΈΡΠ½ΡΠ΅ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΊΠ»Π΅ΡΠΊΠΈ. ΠΡΠ»ΠΈ ΠΏΠΎΠΊΠ°Π·Π°Π½Ρ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Π½Π΅ΠΊΠΎΡΠΎΡΡΡ
ΠΌΠΈΠΊΡΠΎ-Π ΠΠ ΠΏΡΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΡΠ΅ΡΡΠ°Ρ
, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ ΠΏΡΠΈ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΠΈ ΡΠΎΠ»ΠΈΠ΄Π½ΡΡ
ΠΎΡΠ³Π°Π½ΠΎΠ². ΠΡΠ΅Π½ΠΊΠ° ΡΡΠΎΠ²Π½Π΅ΠΉ ΠΌΠΈΠΊΡΠΎ-Π ΠΠ ΠΏΡΠΈ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ Π»Π΅Π³ΠΊΠΈΡ
ΠΌΠΎΠΆΠ΅Ρ ΠΈΠΌΠ΅ΡΡ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π΄Π»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ ΠΈ ΠΏΠΎΠ΄Π±ΠΎΡΠ° ΠΈΠΌΠΌΡΠ½ΠΎΡΡΠΏΡΠ΅ΡΡΠΈΠ²Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΠ°ΠΊΠΎΠΏΠ»Π΅Π½ΠΈΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
Π΄Π°Π½Π½ΡΡ
ΠΎ ΡΠ²ΡΠ·ΠΈ ΠΏΡΠΎΡΠΈΠ»Π΅ΠΉ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΠΌΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π»Π΅Π³ΠΊΠΈΡ
ΠΏΠΎΠΌΠΎΠΆΠ΅Ρ Π² ΠΏΠΎΠΈΡΠΊΠ΅ Π½Π΅ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΎΡΡΠΎΡΠΆΠ΅Π½ΠΈΡ ΠΈ ΡΠ»ΡΡΡΠ΅Π½ΠΈΠΈ ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΡΡ
ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ
ΠΠΈΠΊΡΠΎΠ ΠΠ-27 ΠΈ -339 ΠΏΡΠΈ ΡΠΈΠ±ΡΠΎΠ·Π΅ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΄ΡΠ°: Π°Π½Π°Π»ΠΈΠ· Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΠΈ
Myocardial fibrosis plays a key role in the pathogenesis of heart failure. A family of small non-coding signaling molecules, microRNAs (miRNAs), has been identified as promising profibrogenic biomarkers capable of signaling a possible risk of adverse events after heart transplantation.Objective: to identify and evaluate the diagnostic significance of miRNAs, as well as comprehensive miRNA-based tests in heart recipients with graft myocardial fibrosis.Materials and Methods. The study included 83 heart recipients aged 16 to 64 (48.4 Β± 13.1) years. The expression levels of five microRNAs (miR-27, -101, -142, -339, -424) in venous blood plasma were measured by quantitative real-time polymerase chain reaction; galectin-3 serum levels were determined by enzyme immunoassay.Results. Morphological signs of graft myocardial fibrosis were verified in 48 recipients. The miR-27 and miR-339 expression levels were significantly higher in heart recipients with myocardial fibrosis than in those without myocardial fibrosis (p = 0.018 and p = 0.043, respectively). Diagnostically significant threshold levels of miR-27 and miR-339 for detection of myocardial fibrosis in heart transplant recipients were determined (β4.33 and β5.24 units, respectively). The relative risk of detecting graft myocardial fibrosis in recipients with miR-27 expression value above the threshold level was RR = 1.5 Β± 0.157 [95% CI 1.104-2.039], p = 0.009; for miR-339, RR = 1.31 Β± 0.130 [95% CI 1.018-1.692], p = 0.036. When miR-27 expression levels and galectin-3 serum levels simultaneously exceeded their estimated thresholds, the risk of transplanted heart myocardial fibrosis increased to RR = 2.7 Β± 0.456 [95% CI 1.090-6.524], p = 0.032; when miR-339 and galectin-3 simultaneously exceeded threshold values, the risk was RR = 2.0 Β± 0.316 [95% CI 1.076-3.717], p = 0.028).Conclusion. The miR-27 and miR-339 expression levels are associated with the presence of fibrotic changes in the graft myocardium. The combination of molecular-genetic and proteomic biomarkers in one test improves the diagnostic characteristics of these expressions with respect to post-transplant complications in heart recipients.Π€ΠΈΠ±ΡΠΎΠ· ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΠΈΠ³ΡΠ°Π΅Ρ ΠΊΠ»ΡΡΠ΅Π²ΡΡ ΡΠΎΠ»Ρ Π² ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π΅ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ. Π ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΠΏΡΠΎΡΠΈΠ±ΡΠΎΠ³Π΅Π½Π½ΡΡ
Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ², ΡΠΏΠΎΡΠΎΠ±Π½ΡΡ
ΡΠΈΠ³Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°ΡΡ ΠΎ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΠΌ ΡΠΈΡΠΊΠ΅ Π½Π΅Π³Π°ΡΠΈΠ²Π½ΡΡ
ΡΠΎΠ±ΡΡΠΈΠΉ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΡΠ΅ΡΠ΄ΡΠ°, Π²ΡΠ΄Π΅Π»ΡΡΡ ΡΠ΅ΠΌΠ΅ΠΉΡΡΠ²ΠΎ ΠΌΠ°Π»ΡΡ
Π½Π΅ΠΊΠΎΠ΄ΠΈΡΡΡΡΠΈΡ
ΡΠΈΠ³Π½Π°Π»ΡΠ½ΡΡ
ΠΌΠΎΠ»Π΅ΠΊΡΠ» ΠΌΠΈΠΊΡΠΎΠ ΠΠ.Π¦Π΅Π»Ρ: Π²ΡΡΠ²ΠΈΡΡ ΠΈ ΠΎΡΠ΅Π½ΠΈΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΡΡ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ ΠΌΠΈΠΊΡΠΎΠ ΠΠ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΡΡ
ΡΠ΅ΡΡΠΎΠ² Π½Π° ΠΈΡ
ΠΎΡΠ½ΠΎΠ²Π΅ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° Ρ ΡΠΈΠ±ΡΠΎΠ·ΠΎΠΌ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ°.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 83 ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠ° ΡΠ΅ΡΠ΄ΡΠ° Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 16 Π΄ΠΎ 64 (48,4 Β± 13,1) Π»Π΅Ρ. Π ΠΏΠ»Π°Π·ΠΌΠ΅ Π²Π΅Π½ΠΎΠ·Π½ΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ ΠΈΠ·ΠΌΠ΅ΡΡΠ»ΠΈ ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΏΡΡΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ (miR-27, -101, -142, -339, -424) ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ; ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ Π³Π°Π»Π΅ΠΊΡΠΈΠ½Π°-3 ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΈ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° Π²Π΅ΡΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Ρ Ρ 48 ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ². Π£ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ° Ρ ΡΠΈΠ±ΡΠΎΠ·ΠΎΠΌ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΡΠΎΠ²Π½ΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ miR-27 ΠΈ miR-339 Π·Π½Π°ΡΠΈΠΌΠΎ Π²ΡΡΠ΅, ΡΠ΅ΠΌ ΠΏΡΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΠΈ ΡΠ°ΠΊΠΎΠ²ΠΎΠ³ΠΎ (Ρ = 0,018 ΠΈ Ρ = 0,043 ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ). ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΠ΅ ΠΏΠΎΡΠΎΠ³ΠΎΠ²ΡΠ΅ Π²Π΅Π»ΠΈΡΠΈΠ½Ρ miR-27 ΠΈ miR-339 Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΄ΡΠ° (β4,33 ΠΈ β5,24 ΠΎΡΠ½. Π΅Π΄. ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ). ΠΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΡΠΈΡΠΊ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ° Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Ρ Π²Π΅Π»ΠΈΡΠΈΠ½ΠΎΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ miR-27 Π²ΡΡΠ΅ ΠΏΠΎΡΠΎΠ³ΠΎΠ²ΠΎΠ³ΠΎ ΡΡΠΎΠ²Π½Ρ ΡΠΎΡΡΠ°Π²ΠΈΠ» 1,5 Β± 0,157 [95% ΠΠ 1,104β2,039], Ρ = 0,009; Π΄Π»Ρ miR-339 β 1,31 Β± 0,130 [95% ΠΠ 1,018β1,692], Ρ = 0,036. ΠΡΠΈ ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΌ ΡΡΠΎΠ²Π½Π΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ miR-27 ΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Π³Π°Π»Π΅ΠΊΡΠΈΠ½Π°-3 Π²ΡΡΠ΅ ΠΈΡ
ΡΠ°ΡΡΡΠΈΡΠ°Π½Π½ΡΡ
ΠΏΠΎΡΠΎΠ³ΠΎΠ²ΡΡ
Π·Π½Π°ΡΠ΅Π½ΠΈΠΉ ΡΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΄ΡΠ° Π²ΠΎΠ·ΡΠ°ΡΡΠ°Π΅Ρ Π΄ΠΎ 2,7 Β± 0,456 [95% ΠΠ 1,090β6,524], Ρ = 0,032; ΠΏΡΠΈ ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΌ ΠΏΡΠ΅Π²ΡΡΠ΅Π½ΠΈΠΈ ΠΏΠΎΡΠΎΠ³ΠΎΠ²ΡΡ
Π·Π½Π°ΡΠ΅Π½ΠΈΠΉ miR-339 ΠΈ Π³Π°Π»Π΅ΠΊΡΠΈΠ½Π°-3 ΡΠΈΡΠΊ ΡΠΎΡΡΠ°Π²Π»ΡΠ΅Ρ 2,0 Β± 0,316 [95% ΠΠ 1,076β3,717], Ρ = 0,028).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ miR-27 ΠΈ miR-339 ΡΠ²ΡΠ·Π°Π½Π° Ρ Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ ΡΠΈΠ±ΡΠΎΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ Π² ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ°. Π‘ΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ ΠΏΡΠΎΡΠ΅ΠΎΠΌΠ½ΡΡ
Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π² ΠΎΠ΄Π½ΠΎΠΌ ΡΠ΅ΡΡΠ΅ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΏΠΎΠ²ΡΡΠΈΡΡ Π΅Π³ΠΎ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠΈ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΠΏΠΎΡΡΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ°
ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ ΠΌΠΈΠΊΡΠΎΠ ΠΠ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π»Π΅Π³ΠΊΠΈΡ : ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΈ Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΠΌΠΈ Π΄Π°Π½Π½ΡΠΌΠΈ
Objective: to evaluate the expression levels of miRNA (miR-27, miR-101, miR-142, miR-339 and miR-424) and its relationship with clinical and laboratory parameters in lung transplant recipients. Materials and methods. The study included 57 lung recipients aged 10 to 74 years (35 Β± 15), including six children (9%) β four boys 10, 12, 13 and 17 years and girls 13 and 14 years old β and 51 adult recipients, including 30 men (62.5%). The control group was made up of 14 healthy individuals that were not significantly different by gender and age. Expression levels of the microRNAs studied in blood plasma were determined via quantitative polymerase chain reaction (PCR). Correlations of miRNA expression levels with complete blood count and biochemical blood test indicators were analyzed. Results. Patients with end-stage chronic respiratory failure (potential lung recipients) were found to have significantly higher expression levels of miR-27, miR-101 and miR-339 in plasma than the healthy individuals (p = 0.02, p = 0.03 and p = 0.01, respectively). The expression level of miR-339 correlated with the age of potential lung recipients (p = 0.04). It was a negative correlation (r = β0.46). The expression levels of the other four miRNAs were age independent. The average expression level of miR-424 in lung recipients in the long-term period after lung transplant was higher than in waitlisted patients (p = 0.03). Analysis of the relationship between miRNA expression levels and external respiration function in the long-term post-transplant period showed that miR-142 expression level (r = 0.61; p = 0.04) positively correlates with the Tiffeneau-Pinelli index. This strong correlation, which exceeds 85%, indicates the presence of restrictive lung diseases. A year and more after transplantation, it was found that in the recipients, there were close positive correlations between miR-27, miR-142, miR-424 expression levels and blood leukocyte concentration, as well as between the miR-142 expression level and the sCD40L concentration during this period. Conclusion. A comparative study of the expression level of miRNAs (miR-27, miR-101, miR-142, miR-339 and miR-424) in the blood plasma of patients suffering from end-stage chronic lung diseases of various origin and in lung recipients enables us to conclude that further studies of the miRNA panels are needed in order to assess their effectiveness as potential molecular and genetic markers of post-transplant complications.Π¦Π΅Π»Ρ: ΠΎΡΠ΅Π½ΠΈΡΡ ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ (miR-27, miR-101, miR-142, miR-339 ΠΈ miR-424) ΠΈ Π΅Π΅ ΡΠ²ΡΠ·Ρ Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΠΌΠΈ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠ°ΠΌΠΈ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π»Π΅Π³ΠΊΠΈΡ
. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 57 ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π»Π΅Π³ΠΊΠΈΡ
Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 10 Π΄ΠΎ 74 Π»Π΅Ρ (Π² ΡΡΠ΅Π΄Π½Π΅ΠΌ 35 Β± 15), ΡΡΠ΅Π΄ΠΈ ΠΊΠΎΡΠΎΡΡΡ
ΡΠ΅ΡΡΠ΅ΡΠΎ Π΄Π΅ΡΠ΅ΠΉ (9%) β ΡΠ΅ΡΡΡΠ΅ ΠΌΠ°Π»ΡΡΠΈΠΊΠ° 10, 12, 13 ΠΈ 17 Π»Π΅Ρ ΠΈ Π΄Π΅Π²ΠΎΡΠΊΠΈ 13 ΠΈ 14 Π»Π΅Ρ β ΠΈ 51 Π²Π·ΡΠΎΡΠ»ΡΠΉ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½Ρ, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ 30 ΠΌΡΠΆΡΠΈΠ½ (62,5%). ΠΡΡΠΏΠΏΡ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 14 Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π»ΠΈΡ, Π·Π½Π°ΡΠΈΠΌΠΎ Π½Π΅ ΠΎΡΠ»ΠΈΡΠ°ΡΡΠΈΡ
ΡΡ ΠΏΠΎ ΠΏΠΎΠ»Ρ ΠΈ Π²ΠΎΠ·ΡΠ°ΡΡΡ. Π£ΡΠΎΠ²Π½ΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΡΡ
Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈΡΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ (ΠΠ¦Π ). ΠΡΡΡΠ΅ΡΡΠ²Π»ΡΠ»ΡΡ Π°Π½Π°Π»ΠΈΠ· ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΎΠ½Π½ΡΡ
ΡΠ²ΡΠ·Π΅ΠΉ ΡΡΠΎΠ²Π½Π΅ΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ Ρ ΠΎΡΠ½ΠΎΠ²Π½ΡΠΌΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ ΠΎΠ±ΡΠ΅Π³ΠΎ ΠΈ Π±ΠΈΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·ΠΎΠ² ΠΊΡΠΎΠ²ΠΈ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Ρ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ miR-27, miR-101 ΠΈ miR-339 Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ΅ΡΠΌΠΈΠ½Π°Π»ΡΠ½ΠΎΠΉ ΡΡΠ°Π΄ΠΈΠ΅ΠΉ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π΄ΡΡ
Π°ΡΠ΅Π»ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ (ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π»Π΅Π³ΠΊΠΈΡ
) ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΠΎ Π·Π΄ΠΎΡΠΎΠ²ΡΠΌΠΈ Π»ΠΈΡΠ°ΠΌΠΈ (Ρ = 0,02, Ρ = 0,03 ΠΈ Ρ = 0,01 ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ). ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ ΡΠ΅ΡΡΡΠ΅Ρ
ΠΈΠ· ΠΏΡΡΠΈ Π½Π΅ Π·Π°Π²ΠΈΡΠ΅Π»Π° ΠΎΡ Π²ΠΎΠ·ΡΠ°ΡΡΠ°. Π£ΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ miR-339 ΠΊΠΎΡΡΠ΅Π»ΠΈΡΠΎΠ²Π°Π» Ρ Π²ΠΎΠ·ΡΠ°ΡΡΠΎΠΌ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π»Π΅Π³ΠΊΠΈΡ
(p = 0,04), ΠΈ ΡΠ²ΡΠ·Ρ Π½ΠΎΡΠΈΠ»Π° ΠΎΠ±ΡΠ°ΡΠ½ΡΠΉ Ρ
Π°ΡΠ°ΠΊΡΠ΅Ρ, r = β0,46. Π‘ΡΠ΅Π΄Π½ΡΡ Π²Π΅Π»ΠΈΡΠΈΠ½Π° ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ miR-424 Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π»Π΅Π³ΠΊΠΈΡ
Π² ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ ΠΏΠΎΡΠ»Π΅ Π’Π ΠΎΠΊΠ°Π·Π°Π»Π°ΡΡ Π²ΡΡΠ΅, ΡΠ΅ΠΌ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΎΠΆΠΈΠ΄Π°ΡΡΠΈΡ
ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΡ (Ρ = 0,03). ΠΡΠΈ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠΈ ΡΠ²ΡΠ·ΠΈ ΡΡΠΎΠ²Π½Π΅ΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ ΡΡΠ½ΠΊΡΠΈΠΈ Π²Π½Π΅ΡΠ½Π΅Π³ΠΎ Π΄ΡΡ
Π°Π½ΠΈΡ Π² ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΠΎΠΌ ΠΏΠΎΡΡΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π° Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½Π°Ρ ΠΏΡΡΠΌΠ°Ρ ΡΠ²ΡΠ·Ρ ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ miR-142 (r = 0,61; p = 0,04) Ρ ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠΌ Π’ΠΈΡΡΠ½ΠΎ, Π²Π΅Π»ΠΈΡΠΈΠ½Π° ΠΊΠΎΡΠΎΡΠΎΠ³ΠΎ Π±ΠΎΠ»Π΅Π΅ 85% ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΠ΅Ρ ΠΎ ΡΠ΅ΡΡΡΠΈΠΊΡΠΈΠ²Π½ΡΡ
Π½Π°ΡΡΡΠ΅Π½ΠΈΡΡ
Π΄ΡΡ
Π°ΡΠ΅Π»ΡΠ½ΡΡ
ΠΏΡΡΠ΅ΠΉ. Π§Π΅ΡΠ΅Π· Π³ΠΎΠ΄ ΠΈ Π±ΠΎΠ»Π΅Π΅ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π²ΡΡΠ²Π»Π΅Π½Ρ ΡΠ΅ΡΠ½ΡΠ΅ ΠΏΡΡΠΌΡΠ΅ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΈ ΡΡΠΎΠ²Π½Π΅ΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ miR-27, miR-142 ΠΈ miR-424 Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠΎΠ² Π² ΠΊΡΠΎΠ²ΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ miR-142 Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ sCD40L Π² ΡΡΠΎΡ ΠΏΠ΅ΡΠΈΠΎΠ΄. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π‘ΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ (miR-27, miR-101, miR-142, miR-339 ΠΈ miR-424) Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΡΡΡΠ°Π΄Π°ΡΡΠΈΡ
Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ Π»Π΅Π³ΠΊΠΈΡ
ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠΉ ΡΡΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ Π² ΡΠ΅ΡΠΌΠΈΠ½Π°Π»ΡΠ½ΠΎΠΉ ΡΡΠ°Π΄ΠΈΠΈ, ΠΈ Ρ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Π»Π΅Π³ΠΊΠΈΡ
ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΠ΄Π΅Π»Π°ΡΡ Π·Π°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅ ΠΎ ΡΠ΅Π»Π΅ΡΠΎΠΎΠ±ΡΠ°Π·Π½ΠΎΡΡΠΈ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΏΠ°Π½Π΅Π»ΠΈ ΠΌΠΈΠΊΡΠΎΠ ΠΠ Π΄Π»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΈΡ
ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΏΠΎΡΡΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ
ST2 IN REJECTION OF THE TRANSPLANTED HEART
This review summarizes the current literature devoted to the analysis of prognostic role of ST2 biomarker in rejection of the transplanted heart. ST2 is one of the most promising diagnostic markers of the development and severity of heart failure as well as the mortality risk in patients with cardiovascular diseases. ST2 is expressed in cardiomyocytes in response to a variety of pathological processes and mechanical damage to the heart, which allows diagnosing cardiovascular diseases before clinical manifestations. Presumably, measuring the level of ST2 in heart transplant may have diagnostic and prognostic value in the assessment of graft and risk of rejection. Currently, accumulated clinical data on the role of given biomarker in heart transplantation are not enough, and further research on the relation of ST2 levels with different clinical and laboratory parameters in heart recipients is necessary